Back to News
Market Impact: 0.2
Benitec Biopharma FY26 Net Loss Widens; BB-301 Interim Data Due In October
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCorporate Guidance & Outlook
Benitec Biopharma reported full-year fiscal 2026 financial results for the year ended June 30, 2026, and updated investors on upcoming clinical milestones for BB-301, its lead investigational candidate. The provided article text does not disclose financial figures, trial data, or specific milestone timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
BNTC0.35
More News
- Trump called out Big Oil profits. Here’s how much their refining earnings have surged since
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Wall Street Punishes Tech Stocks on Earnings Misses
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Big Oil Scores $56 Billion Windfall on Spiking Fuel Prices
- Intel plunged 28.6% for its worst drop since 1974 — and the AI sell-off gave the S&P 500 its worst day since June